quilizumab   Click here for help

GtoPdb Ligand ID: 8998

Synonyms: 47H4 v5 hulgG1 [4] | MEMP1972A | RG-7449
Immunopharmacology Ligand
Compound class: Antibody
Comment: Quilizumab is a humanized IgG1κ investigational monoclonal antibody designed to bind the M1' segment of membrane-bound immunoglobulin E (mIgE), which is part of the B-cell receptor (BCR) on B cells [1].
Peptide sequences and 3D structural information for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals 100% matches with sequences claimed in patent US8071097 B2 [4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial evaluating quilizumab as a treatment for refractory chronic spontaneous urticaria (NCT01987947) has been completed. The quilizumab development programme was terminated. Alternative anti-IgE agents are still in development, including United BioPharma's UB-221 (humanized anti-IgE mAb; Phase 2 chronic urticaria NCT05298215) [2] and DARPin-based IgE inhibitors [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01987947 A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria Phase 2 Interventional Genentech, Inc.